AbSorber
Latest news
-
2009-12-09
AbSorber receives European patent protection for its transplantation cross match-test XM-ONE® -
2009-07-02
AbSorber AB announced today a new global distribution partner for the transplantation diagnostic product XM-ONE® effective from July 1, 2009. -
2009-05-05
Professor Ron Shapiro, Pittsburgh, PA, discusses the XM-ONE Multicenter Study... -
2009-03-02
AbSorber’s transplantation crossmatch test XM-ONE® was evaluated in a large clinical study...
A Tool for enhanced risk assessment
The last decades there has been a substantial increase in short-term and long-term survival of transplanted grafts from both living and diseased donors (1). Nevertheless acute rejection affecting long-term graft survival remains a significant problem. Despite lymphocyte cross-matches, approximately 15-20% of kidneys undergo early rejections (2).
1. Hariharan S et al, N Engl J Med 2000, 342:605-12. 2. Sumitran-Holgersson S and Holgersson J, Current Opinion in Organ Transplantation 2006, 11:425-432. 3. Breimer, M et al, Transplantation 2009, 87(4):549-556.
AbSorber
AbSorber AB is a biotech company focused on developing products that increase the probability of transplantation success. XM-ONE®, the first AbSorber product on the market, is a CE-marked and FDA registered transplantation crossmatch test kit. In contrast to current crossmatch testing, XM-ONE® rapidly detects antibodies specific for endothelial-specific antigens as well as antibodies specific to major transplantation antigens. read more»
Highlighted Meeting
| Date: | May 1-5, 2010 |
| Location: | San Diego, California |
Newsletter
Get information on XM-ONE® and stay tuned with AbSorber through our newsletter.